U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Undetectable visual evoked potentials

MedGen UID:
376697
Concept ID:
C1850069
Finding
Synonym: Absence of visual evoked potentials
 
HPO: HP:0007965

Term Hierarchy

Conditions with this feature

Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome
MedGen UID:
318633
Concept ID:
C1832466
Disease or Syndrome
ATP1A3-related neurologic disorders represent a clinical continuum in which at least three distinct phenotypes have been delineated: rapid-onset dystonia-parkinsonism (RDP); alternating hemiplegia of childhood (ACH); and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS). However, some affected individuals have intermediate phenotypes or only a few features that do not fit well into one of these major phenotypes. RDP has been characterized by: abrupt onset of dystonia over days to weeks with parkinsonism (primarily bradykinesia and postural instability); common bulbar involvement; and absence or minimal response to an adequate trial of L-dopa therapy, with few exceptions. Often fever, physiologic stress, or alcoholic binges trigger the onset of symptoms. After their initial appearance, symptoms often stabilize with little improvement; occasionally second episodes occur with abrupt worsening of symptoms. Rarely, affected individuals have reported a more gradual onset of symptoms over weeks to months. Anxiety, depression, and seizures have been reported. Age of onset ranges from four to 55 years, although a childhood variation of RDP with onset between ages nine and 14 months has been reported. AHC is a complex neurodevelopmental syndrome most frequently manifesting in infancy or early childhood with paroxysmal episodic neurologic dysfunction including alternating hemiparesis or dystonia, quadriparesis, seizure-like episodes, and oculomotor abnormalities. Episodes can last for minutes, hours, days, or even weeks. Remission of symptoms occurs with sleep and immediately after awakening. Over time, persistent neurologic deficits including oculomotor apraxia, ataxia, choreoathetosis, dystonia, parkinsonism, and cognitive and behavioral dysfunction develop in the majority of those affected; more than 50% develop epilepsy in addition to their episodic movement disorder phenotype. CAPOS (cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss) syndrome is characterized by episodes of ataxic encephalopathy and/or weakness during and after a febrile illness. Onset is between ages six months and four years. Some acute symptoms resolve; progression of sensory losses and severity vary.
Mitochondrial complex I deficiency
MedGen UID:
374101
Concept ID:
C1838979
Disease or Syndrome
Isolated complex I deficiency is a rare inborn error of metabolism due to mutations in nuclear or mitochondrial genes encoding subunits or assembly factors of the human mitochondrial complex I (NADH: ubiquinone oxidoreductase) and is characterized by a wide range of manifestations including marked and often fatal lactic acidosis, cardiomyopathy, leukoencephalopathy, pure myopathy and hepatopathy with tubulopathy. Among the numerous clinical phenotypes observed are Leigh syndrome, Leber hereditary optic neuropathy and MELAS syndrome (see these terms).
PEHO syndrome
MedGen UID:
342404
Concept ID:
C1850055
Disease or Syndrome
PEHO is a severe autosomal recessive neurodevelopmental disorder characterized by extreme cerebellar atrophy due to almost total loss of granule neurons. Affected individuals present in early infancy with hypotonia, profoundly delayed psychomotor development, optic atrophy, progressive atrophy of the cerebellum and brainstem, and dysmyelination. Most patients also develop infantile seizures that are often associated with hypsarrhythmia on EEG, and many have peripheral edema (summary by Anttonen et al., 2017).
Autosomal recessive osteopetrosis 5
MedGen UID:
409627
Concept ID:
C1968603
Disease or Syndrome
Autosomal recessive osteopetrosis-5 (OPTB5) is a form of infantile malignant osteopetrosis, characterized by defective osteoclast function resulting in decreased bone resorption and generalized osteosclerosis. Defective resorption causes development of densely sclerotic fragile bones and progressive obliteration of the marrow spaces and cranial foramina. Marrow obliteration is associated with extramedullary hematopoiesis and hepatosplenomegaly, and results in anemia and thrombocytopenia, whereas nerve entrapment accounts for progressive blindness and hearing loss. Other major manifestations include failure to thrive, pathologic fractures, and increased infection rate. Most affected children succumb to severe bone marrow failure and overwhelming infection in the first few years of life (summary by Quarello et al., 2004).
Warburg micro syndrome 2
MedGen UID:
481844
Concept ID:
C3280214
Disease or Syndrome
RAB18 deficiency is the molecular deficit underlying both Warburg micro syndrome (characterized by eye, nervous system, and endocrine abnormalities) and Martsolf syndrome (characterized by similar – but milder – findings). To date Warburg micro syndrome comprises >96% of reported individuals with genetically defined RAB18 deficiency. The hallmark ophthalmologic findings are bilateral congenital cataracts, usually accompanied by microphthalmia, microcornea (diameter <10), and small atonic pupils. Poor vision despite early cataract surgery likely results from progressive optic atrophy and cortical visual impairment. Individuals with Warburg micro syndrome have severe to profound intellectual disability (ID); those with Martsolf syndrome have mild to moderate ID. Some individuals with RAB18 deficiency also have epilepsy. In Warburg micro syndrome, a progressive ascending spastic paraplegia typically begins with spastic diplegia and contractures during the first year, followed by upper-limb involvement leading to spastic quadriplegia after about age five years, often eventually causing breathing difficulties. In Martsolf syndrome infantile hypotonia is followed primarily by slowly progressive lower-limb spasticity. Hypogonadism – when present – manifests in both syndromes, in males as micropenis and/or cryptorchidism and in females as hypoplastic labia minora, clitoral hypoplasia, and small introitus.
Mitochondrial complex 4 deficiency, nuclear type 7
MedGen UID:
1754683
Concept ID:
C5436685
Disease or Syndrome
Mitochondrial complex IV deficiency nuclear type 7 (MC4DN7) is an autosomal recessive metabolic encephalomyopathic disorder with highly variable manifestations. Only a few patients have been reported. Some patients have normal early development then show rapid neurodegeneration with progressive muscle weakness, gait disturbances, and cognitive decline in mid to late childhood. Other features may include seizures and visual impairment. Brain imaging shows progressive leukodystrophy with cystic lesions. In contrast, at least 1 patient has been reported who presented in the neonatal period with metabolic acidosis, hydrocephalus, hypotonia, and cortical blindness. This patient developed hypertrophic cardiomyopathy resulting in early death. All patients had increased serum lactate and decreased levels and activity of mitochondrial respiratory complex IV (summary by Massa et al., 2008 and Abdulhag et al., 2015). For a discussion of genetic heterogeneity of mitochondrial complex IV (cytochrome c oxidase) deficiency, see 220110.

Recent clinical studies

Etiology

Desjardins JA, Segalowitz SJ
J Vis 2013 Apr 25;13(5) doi: 10.1167/13.5.22. PMID: 23620532
Xue K, Wang M, Qian J, Yuan Y, Zhang R
Eur J Ophthalmol 2013 Jul-Aug;23(4):571-7. Epub 2013 Mar 12 doi: 10.5301/ejo.5000262. PMID: 23483502
Ko KF
Singapore Med J 2010 Sep;51(9):716-20. PMID: 20938612
Suttle CM, Turner AM
Ophthalmic Physiol Opt 2004 Mar;24(2):91-9. doi: 10.1046/j.1475-1313.2003.00174.x. PMID: 15005673
Kamitani T, Kuroiwa Y, Wang L, Li M, Suzuki Y, Takahashi T, Ikegami T, Matsubara S
J Neurol 2002 Aug;249(8):975-82. doi: 10.1007/s00415-002-0764-7. PMID: 12195440

Diagnosis

Kleerekooper I, Del Porto L, Dell'Arti L, Guajardo J, Leo S, Robson AG, Trip SA, Petzold A, Plant GT, Holder GE
Doc Ophthalmol 2022 Dec;145(3):185-195. Epub 2022 Sep 26 doi: 10.1007/s10633-022-09896-6. PMID: 36161379
Majoulet A, Audo I, Goujard C, De Menthon M, Chaix F, Safar P, Labetoulle M, Rousseau A
Doc Ophthalmol 2022 Apr;144(2):147-152. Epub 2022 Jan 3 doi: 10.1007/s10633-021-09860-w. PMID: 34978660
Habek M, Adamec I, Barun B, Crnošija L, Gabelić T, Krbot Skorić M
Adv Exp Med Biol 2017;958:129-139. doi: 10.1007/978-3-319-47861-6_8. PMID: 28093711
Suttle CM, Turner AM
Ophthalmic Physiol Opt 2004 Mar;24(2):91-9. doi: 10.1046/j.1475-1313.2003.00174.x. PMID: 15005673
Otto DA, Fox DA
Neurotoxicology 1993 Summer-Fall;14(2-3):191-207. PMID: 8247393

Therapy

Fisher AC, McCulloch DL, Borchert MS, Garcia-Filion P, Fink C, Eleuteri A, Simpson DM
Doc Ophthalmol 2015 Aug;131(1):25-34. Epub 2015 Mar 12 doi: 10.1007/s10633-015-9493-y. PMID: 25761929
Eimer M, Mazza V
Psychophysiology 2005 May;42(3):328-42. doi: 10.1111/j.1469-8986.2005.00285.x. PMID: 15943687Free PMC Article
Koivisto M, Revonsuo A
Psychophysiology 2003 May;40(3):423-9. doi: 10.1111/1469-8986.00044. PMID: 12946115
Bernat E, Shevrin H, Snodgrass M
Clin Neurophysiol 2001 Jan;112(1):159-71. doi: 10.1016/s1388-2457(00)00445-4. PMID: 11137675
Buchsbaum MS, Lee S, Haier R, Wu JC, Green M, Tang SW
Neuropsychobiology 1988;20(1):15-22. doi: 10.1159/000118467. PMID: 3068567

Prognosis

Steinhauser M, Andersen SK
Neuroimage 2019 Feb 1;186:83-92. Epub 2018 Oct 23 doi: 10.1016/j.neuroimage.2018.10.059. PMID: 30366075Free PMC Article
Kalfaoğlu Ç, Stafford T, Milne E
J Exp Psychol Hum Percept Perform 2018 Jan;44(1):69-88. Epub 2017 Apr 27 doi: 10.1037/xhp0000417. PMID: 28447844
Qu Z, Hillyard SA, Ding Y
Cereb Cortex 2017 Feb 1;27(2):1512-1523. doi: 10.1093/cercor/bhv342. PMID: 26759483
Alexander P, Wen Y, Baxter JM, Tint NL, Browning AC, Amoaku WM
Doc Ophthalmol 2012 Oct;125(2):169-78. Epub 2012 Jun 23 doi: 10.1007/s10633-012-9339-9. PMID: 22729668
Ko KF
Singapore Med J 2010 Sep;51(9):716-20. PMID: 20938612

Clinical prediction guides

Ilse A, Donohue SE, Schoenfeld MA, Hopf JM, Heinze HJ, Harris JA
Appetite 2020 Dec 1;155:104828. Epub 2020 Aug 16 doi: 10.1016/j.appet.2020.104828. PMID: 32814119
Kalfaoğlu Ç, Stafford T, Milne E
J Exp Psychol Hum Percept Perform 2018 Jan;44(1):69-88. Epub 2017 Apr 27 doi: 10.1037/xhp0000417. PMID: 28447844
Qu Z, Hillyard SA, Ding Y
Cereb Cortex 2017 Feb 1;27(2):1512-1523. doi: 10.1093/cercor/bhv342. PMID: 26759483
Bergmann K, Schubert AL, Hagemann D, Schankin A
Psychol Res 2016 Jul;80(4):660-76. Epub 2015 May 9 doi: 10.1007/s00426-015-0669-6. PMID: 25957278
Otto DA, Fox DA
Neurotoxicology 1993 Summer-Fall;14(2-3):191-207. PMID: 8247393

Supplemental Content

Table of contents

    Clinical resources

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...